Seattle-area biotech company Athira Pharma agreed to pay $4.07 million to settle allegations that it violated the False ...

Bothell-based biopharmaceutical company Athira Pharma Inc. (Nasdaq: ATHA) is paying a $4.1 million fine due to allegations it ...

U.S. pharmaceutical company pays $4.07 million to resolve allegations that it violated the False Claims Act (FCA) by failing ...

A biopharmaceutical company, Athira Pharma, settled for $4.068 million over allegations of research misconduct.

Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of ...

A pharmaceutical company in Bothell has agreed to pay $4,068,698 to settle allegations it used falsified research to obtain ...

Florida physician Stephen Andrew Leedy, MD, has been accused of producing child sexual abuse materials and enticing minors to ...

Stressing the importance of integrity in taxpayer-funded biomedical research, the U.S. Department of Justice reported that Athira Pharma Inc. agreed to pay more than $4 million to resolve False Claims ...

BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

CEO Mark James Litton sold 25,107 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $0.56, for a total transaction of $14,059.92. Following the ...

Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of research misconduct to the National Institutes of ...